Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05190978

Randomized Feasibility Trial for Mesh in Pre-Pectoral Reconstruction

Surgical mesh products, particularly acellular dermal matrices (ADM), are now used by the majority of plastic surgeons to assist with the nearly 100,000 prosthetic breast reconstruction procedures in the United States, despite never being approved by Food and Drug Administration (FDA) for this indication. As surgeons transition to placing breast implants above the chest muscle (pre-pectoral), there has been an increasing reliance on these often expensive mesh products without robust evidence to understand their risks and benefits. Our pilot study is a randomized multi-center trial to evaluate surgical mesh assistance in pre-pectoral tissue expander to breast implant reconstruction to address vital questions for women's public health.

Recruiting

Interested in participating?

Request Info

Key information

Age range

22 year–75 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

University of California Los Angeles

Los Angeles, California, 90095, United States

Location status: Recruiting

Location contact

Ginger Slack, MD

SUB_INVESTIGATOR

Jaco Festekjian, MD

CONTACT

310 825 5510

Jaco Festekjian, MD

PRINCIPAL_INVESTIGATOR

Michael DeLong, MD

PRINCIPAL_INVESTIGATOR

Michael Delong, MD

CONTACT

[email protected]

310 825 5510

About this study

One in eight women will develop breast cancer in her lifetime, causing both physical and psychological trauma due to invasive treatments and the distress associated with removal of a breast. Breast reconstruction after mastectomy has become a critical procedure for many women to restore psychological wellbeing, with implant-based reconstruction the most common approach. Nearly 100,000 patients undergo reconstruction with implants every year in the United States.

Surgical mesh devices, particularly acellular dermal matrices, are now used off-label by most reconstructive surgeons performing prosthetic breast reconstruction. In the past decade, surgeons have advocated a transition from submuscular reconstruction (placement of the implant under the pectoralis muscle) to pre-pectoral (placement above the pectoralis) and often consider mesh to be necessary for this procedure. Surgical mesh has not been approved by the FDA for breast reconstruction for either anatomic location. These mesh devices are considered Class III medical devices and FDA recently prioritized the evaluation of these products during a panel meeting in 2019.

No Level I randomized trial has been successfully performed to determine the actual risks and benefits of mesh devices in breast reconstruction. This study proposes a pilot study as the first ever randomized, multi-center trial for mesh assistance in two-stage prosthetic pre-pectoral breast reconstruction, across the major manufacturers. The goals are to demonstrate feasibility of such a study and to generate high level data toward the evaluation of safety and effectiveness of these products for the benefit of women's public health

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Female patients age 22 to 75 undergoing unilateral or bilateral immediate pre-pectoral reconstruction with tissue expanders
  • Prophylactic and oncologic mastectomies are both acceptable
  • Nipple sparing and skin sparing mastectomy techniques are both acceptable

Exclusion criteria

  • Intraoperative assessment demonstrates unfavorable conditions (ie poor mastectomy skin flap thickness or viability) for immediate pre-pectoral reconstruction in any breast
  • Bilateral reconstruction patients undergoing contralateral submuscular reconstruction
  • Direct-to-implant reconstruction
  • Pregnancy
  • Delayed reconstruction

Treatment and study plan

Acellular Dermal Matrix

Device

Acellular dermal matrix will surgically implanted around the tissue expanders in patients in the ADM cohort.

Reconstruction without ADM

Procedure

Acellular dermal matrix will not be surgically implanted around the tissue expanders in patients in the control cohort.

Primary outcomes

  1. Safety - Major Complications

    Time frame: 2 years

    Relative rate of major complications (requiring unplanned re-admission or re-operation)

  2. Effectiveness - BREASTQ

    Time frame: 2 years

    BREAST-Q validated patient reported questionnaire to assess results of final reconstruction.

Secondary outcomes

  1. Secondary Effectiveness

    Time frame: 2 years

    Time from expander placement to implant exchange

  2. Secondary Safety

    Time frame: 2 years

    Individual complication rates

  3. Capsular Contracture

    Time frame: 2 years

    Rate of capsular contracture

Study contacts

Contact information is provided by the study sponsor or research team.

Jaco Festekjian, MD

CONTACT

(310) 825-5510

Michael Delong, MD

CONTACT

[email protected]

(310) 825-5510

Sponsors and collaborators

Lead sponsor

University of California, Los Angeles

Other

Collaborators

  • University of California, Davis
  • University of California, San Francisco
  • University of Utah
  • Weill Medical College of Cornell University
  • Yale University

Registry information

Important dates

Study start
2022
Primary completion
2027
Study completion
2027
First posted
Jan 13, 2022
Registry last updated
May 5, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.